6 news items
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
CLDX
15 May 24
"forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
CLDX
6 May 24
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
CLDX
17 Apr 24
statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
CLDX
8 Mar 24
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
CLDX
5 Mar 24
"forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements
80bipxe3 yux2n4vcxuwurjrki2
CLDX
5 Mar 24
Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends
- Prev
- 1
- Next